Similar articles

• Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries.

  Mengesha T, Makonnen E. Mengesha T, et al. East Afr Med J. 1999 Jun;76(6):314-9. East Afr Med J. 1999. PMID: 10750517
• [OCULAR COMPLICATIONS OBSERVED DURING SYNTHETIC ANTIMALARIAL TREATMENT].

  BEGUE JJ. BEGUE JJ. Clinique (Paris). 1964 May;59:287-91. Clinique (Paris). 1964. PMID: 14171653 Review. French. No abstract available.
• Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine.

  Steketee RW, Wirima JJ, Slutsker L, Khoromana CO, Heymann DL, Breman JG. Steketee RW, et al. Am J Trop Med Hyg. 1996;55(1 Suppl):50-6. doi: 10.4269/ajtmh.1996.55.50. Am J Trop Med Hyg. 1996. PMID: 8702037
• Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature.

  Osadchy A, Ratnapalan T, Koren G. Osadchy A, et al. J Rheumatol. 2011 Dec;38(12):2504-8. doi: 10.3899/jrheum.110686. Epub 2011 Oct 15. J Rheumatol. 2011. PMID: 22002012 Review.
• In vivo and in vitro antimalarial effect and toxicological evaluation of the chloroquine analogue PQUI08001/06.

  Reis PA, Pais KC, Pereira MF, Douradinha B, Costa NF, Kaiser CR, Bozza PT, Areas ALL, Zalis MG, de Lima Ferreira M, de Souza MVN, da Silva Frutuoso V, de Castro-Faria-Neto HC. Reis PA, et al. Parasitol Res. 2018 Nov;117(11):3585-3590. doi: 10.1007/s00436-018-6057-6. Epub 2018 Aug 25. Parasitol Res. 2018. PMID: 30145706